TCM
JBIO

TCG Crossover Management’s Jade Biosciences JBIO Stock Holding History

TCG Crossover Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-64,023
Closed -$640K – 41
2025
Q2 		$640K Hold
64,023
– – 0.07% 36
2025
Q1 		$5.62M Hold
64,023
– – 0.77% 30
2024
Q4 		$5.94M Hold
64,023
– – 0.58% 34
2024
Q3 		$4.68M Hold
64,023
– – 0.4% 31
2024
Q2 		$3.72M Buy
64,023
+1,129
+2% +$749K 0.39% 28
2024
Q1 		$65.1M Hold
62,894
– – 5.15% 6
2023
Q4 		$49.8M Hold
62,894
– – 5.52% 6
2023
Q3 		$29.9M Hold
62,894
– – 4.4% 9
2023
Q2 		$37.8M Buy
62,894
+32,000
+104% +$20.5M 6.19% 5
2023
Q1 		$21.8M Hold
30,894
– – 4.25% 10
2022
Q4 		$31.7M Buy
30,894
+3,478
+13% +$2.53M 5.59% 7
2022
Q3 		$15.9M Buy
27,416
+2,000
+8% +$1.34M 4.77% 9
2022
Q2 		$13.9M Hold
25,416
– – 5.91% 9
2022
Q1 		$16.3M Buy
25,416
+1,035
+4% +$402K 6.55% 7
2021
Q4 		$10.1M Buy
+24,381
New +$12.3M 4.71% 10

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

TCG Crossover Management's JBIO Position: Q3 2025 in Review

TCG Crossover Management sold out of Jade Biosciences (JBIO) in Q3 2025, closing a stake of 64,023 shares — an estimated $640K sold.

TCG Crossover Management first reported a position in JBIO in Q4 2021 and held it in 15 quarters. The position peaked at $65.1M in Q1 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q3 2025.

  • TCG Crossover Management reported no remaining Jade Biosciences position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 64,023 Jade Biosciences shares in Q3 2025, an estimated $640K.
  • TCG Crossover Management first reported a position in Jade Biosciences in Q4 2021 and held it in 15 quarters.
  • TCG Crossover Management's Jade Biosciences position peaked at $65.1M in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.